- New Company, Assembly Biosciences, to Focus on First-in Class Technology for Treatment and Potential Cure of Hepatitis B Virus Infection, Affecting 350 Million Worldwide
- Projected Multi-Billion Market Opportunity; No Curative Therapy Exists
- Combined Teams Bring Experienced Leadership Capable of Driving Value
- Anticipated Closing July 10, 2014, Pending Shareholder Approval
Click here to view Proxy Statement
To close, click the Close button or hit the ESC key.